Molecule Details
| InChIKey | COSPVUFTLGQDQL-UHFFFAOYSA-N |
|---|---|
| Compound Name | Nelotanserin |
| Canonical SMILES | COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 8.1 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB12555 |
|---|---|
| Drug Name | Nelotanserin |
| CAS Number | 839713-36-9 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Nelotanserin has been used in trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and REM Sleep Behavior Disorder. It is a highly selective antagonist at the 5-HT2A serotonin receptor. It increases non-REM sleep, the most restorative phase of the sl... |
Categories: Amides Benzene Derivatives
Cross-references: BindingDB: 50324541 CHEMBL598172 ChemSpider: 9858284 PubChem:11683556 PubChem:347828779 Wikipedia: Nelotanserin ZINC: ZINC000038239930
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P28223 | HTR2A | 5-hydroxytryptamine receptor 2A | modulator | targets |